Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MicroPine is an investigational ophthalmic spray formulation of atropine, delivered via Eyenovia’s proprietary Optejet microdose dispenser. It is being developed as a treatment to slow the progression of pediatric progressive myopia (nearsightedness) in children. The drug-device combination aims to provide precise, low-dose delivery of atropine directly to the eye as a gentle mist, potentially improving compliance and reducing systemic exposure compared to traditional eye drops. Atropine acts as a non-selective muscarinic acetylcholine receptor antagonist in the eye, which has been shown in clinical studies to slow axial elongation and myopic progression by up to 60%. MicroPine is currently in late phase III clinical trials for this indication and has not yet received FDA approval[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MicroPine.